Jpmorgan Chase & CO Protalix Bio Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,595 shares of PLX stock, worth $2,057. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,595
Previous 32,518
95.1%
Holding current value
$2,057
Previous $40,000
97.5%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding PLX
# of Institutions
64Shares Held
5.79MCall Options Held
103KPut Options Held
4.6K-
Israel Englander Millennium Management LLC | New York, Ny811KShares$1.05 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny805KShares$1.04 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY462KShares$595,9250.0% of portfolio
-
Gsa Capital Partners LLP London, X0435KShares$561,4240.03% of portfolio
-
Northern Trust Corp Chicago, IL423KShares$545,9440.0% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $64.2M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...